328061-33-2

Basic information

• Product Name: 2-Pyrimidinamine, 4-(2-methylimidazo[1,2-a]pyridin-3-yl)-N-phenyl-
• CAS NO: 328061-33-2
• Molecular Formula: C18H15N5
• Molecular Weight: 301.351
• Mol File: 328061-33-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-Pyrimidinamine, 4-(2-methylimidazo[1,2-a]pyridin-3-yl)-N-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyrimidinamine, 4-(2-methylimidazo[1,2-a]pyridin-3-yl)-N-phenyl-(328061-33-2)
• EPA Substance Registry System: 2-Pyrimidinamine, 4-(2-methylimidazo[1,2-a]pyridin-3-yl)-N-phenyl-(328061-33-2)

Safety Data

• Hazardous Substances Data: 328061-33-2(Hazardous Substances Data)

Upstream product

• 3043-28-5 3-bromopentane-2,4-dione 
• 504-29-0 2-aminopyridine 
• 264606-78-2 4-(2-methyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidine-2-thiol 
• 1694-29-7 3-chloropentane-2,4-dione 
• 29096-60-4 1-(2-methylimidazo[1,2-a]pyridin-3-yl)ethanone 
• 62-53-3 aniline 
• 264127-50-6 4-(2-methylimidazo[1,2-a]pyrid-3-yl)-2-methylthiopyrimidine 
• 2002-16-6 1-phenylguanidine 

Relevant articles and documents

Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors

Exploration of SAR and optimisation of the imidazo[1,2-a]pyridine CDK inhibitors has lead to the discovery of novel, potent and selective inhibitors of the cyclin-dependent kinase CDK2. Understanding of SAR has identified positions of substitution, which allow modification of physical properties and offer the potential for in vivo optimisation.

IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES

A compound of formula (I) wherein Ring A is imidazol[1,2a]pyrid-3-yl or pyrazolo[2,3a]pyrid-3-yl; Ris as defined within; m is 0-5; wherein the values of Rmay be the same or different; Ris as defined within; n is 0 to 2, wherein the values of Rmay be the same or different; Ring B is phenyl or phenyl fused to a C5-7cycloalkyl ring; Ris as defined within; p is 0-4; wherein the values of Rmay be the same or different; Ris as defined within; q is 0-2; wherein the values of Rmay be the same or different; and wherein p+q=5; or a pharmaceutically acceptable salt or an in vivo hydrolyzable ester thereof is described. The use of compounds of formula (I) in the inhibition of cell cycle kinases CDK2, CDK4, and CDK6 are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.